Skip to content

Funding Announcements

Filter

Filter & sort

Keyword

Tag

Round

Sort by

Clear

The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.

Announcements

1,485

Total raised

£42.6B

disclosed amounts

This month

£55.3M

raised so far

Seed
£5.1M

The Seed round was led by Macquarie Group and Blackfinch Ventures to fund international expansion and product development.

"Mid-market companies are being held to the same standard as the biggest corporates but they don’t have access to the same tools, leaving many to struggle with outdated systems and processes. Bracket automates that operational layer using AI to give teams real-time visibility and control over bank data and key information, all within one platform. This funding allows us to continue on our growth trajectory and scale our products internationally."
— Pierre Anderson, Co-CEO and Co-founder
Seed
£2.0M

The seed round was led by Osney Capital with backing from several venture firms to scale technical teams and product development.

"The AI security industry is trying to secure the wrong thing. Models will always be vulnerable to adversarial inputs – that’s a fundamental property of how they work. But what happens when an agent is live in production, interacting with real systems, and its behaviour starts to drift? Right now, most teams have no idea. Overmind provides the deployment-layer infrastructure needed to monitor agent interactions and intervene before damage occurs."
— Tyler Edwards, Co-Founder and CEO
Seed
£2.8M

The seed round was led by MMC Ventures with participation from Episode 1 Ventures and Seedcamp to fund team expansion and product development.

"The pharmaceutical industry has made tremendous strides in AI for hit identification and lead optimisation, but target safety assessment has lagged behind. Sable is positioned to change that by making comprehensive safety data accessible and actionable. We’re thrilled that with this funding, we can build the definitive platform for drug target safety."
— Josh Almond-Thynne, co-founder and CEO
Seed
£2.5M

The biotechnology funding pairs strategic capital with a collaborative agreement to explore oncology opportunities.

"This strategic investment is an important endorsement of AMPLY's platform and our approach to oncology. We're building a company designed for partnering – generating high-quality, data-driven programmes and taking them to clear inflection points. We're delighted to welcome Keeps Biomed as a strategic investor, and to bring Oliver on board as CSO to help sharpen our oncology execution and partnering readiness."
— Ben Thomas, CEO